Hubbry Logo
ActiviaActiviaMain
Open search
Activia
Community hub
Activia
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Activia
Activia
Activia
View on Wikipedia
from Wikipedia

Activia
Product typeDairy
OwnerDanone
CountryFrance
Introduced1987; 39 years ago (1987)
Websiteactivia.us.com

Activia is a brand of yogurt owned by Groupe Danone (Dannon in the United States) and introduced in France in 1987. As of 2013, Activia is present in more than 70 countries and on 5 continents. Activia is classified as a functional food,[1] designed to improve digestive health.[2]

In the 1980s, Danone researchers took interest in bifidobacteria. They developed a specific strain that can survive in the acidic medium of yogurt. In addition to traditional yogurt bacteria, they decided to add a probiotic strain. Activia products thus contain Bifidobacterium animalis DN 173,010, a proprietary strain of Bifidobacterium, a probiotic which is marketed by Dannon under the trade names Bifidus Regularis, Bifidus Actiregularis, Bifidus Digestivum and Bifidobacterium Lactis.[3] Danone launched Activia in France in 1987 under the "Bio" brand name.[4] The claims of health benefits have led to lawsuits in the European Union, Canada, and the United States, all of which have resulted in Danone having to modify their advertisement and pay compensations to customers.[5][6]

Introductions into new countries

[edit]

By 2006, the brand was operating in 22 countries. In 2013, it was sold in more than 70 countries.[9]

Products in 2013

[edit]

Activia products are sold with different textures (set or firm, stirred, drinkable, etc.) and in flavors adapted to local consumer preferences. The product line varies by country. Most Activia yogurts contain real fruit.

America

[edit]

United States

[edit]
  • Activia: a yogurt that consists of cherry, prune, strawberry banana, peach, mixed berry, blueberry, strawberry, vanilla[10]
  • Activia Light: strawberry banana, key lime, raspberry, blueberry, peach, strawberry, vanilla
  • Activia Harvest Picks: cherry, mixed berry, peach, strawberry
  • Activia Breakfast Blend: apple cinnamon, maple and brown sugar, banana bread, vanilla
  • Activia Fiber: peach cereal, strawberry cereal, vanilla cereal
  • Activia Drinks: mango, peach, prune, strawberry, strawberry banana
  • Activia 24 oz. Tubs: vanilla light, plain, vanilla

Canada

[edit]
  • Activia: blueberry, vanilla, raspberry, strawberry, strawberry rhubarb, prune, peach, cherry, lemon, plain unsweetened, plain sweetened, apple and blackberry[11]
  • Activia source of fiber: strawberry kiwi cereal, red fruits cereal, peach cereal, vanilla cereal, blueberry cereal
  • Activia fat free: strawberry, vanilla, raspberry, peach
  • Drinkable Activia: strawberry, vanilla, mixed berry

Brazil

[edit]

In Brazil, both yogurt and yogurt-drinks are available. In addition to the usual worldwide fruit flavors, honey with carrot is also available. The "light" line is marketed as "0%" fat.[12]

Europe

[edit]

In Bulgaria, Croatia, and Romania the products include semi-solid yogurts (plain, cereal, strawberry, peach and prune) and yogurt drinks (plain, cereal, strawberry-kiwi and cherry-vanilla).[citation needed]

In Finland the Activia brand includes fruit and natural yogurt as well as yogurt drinks. Lactose free forms of the yogurt are also sold.

In France, semi-solid yogurt and yogurt with fruit layers are available. Unique flavors include coconut. The "light" series is marketed as "0%" fat.[13]

In Spain there are over 57 different flavors.[citation needed]

Following a European law which forbids non-organic food to be labeled "Bio", Danone changed Spanish "Bio"-branded products to the "Activia" brand in order to comply with the law.[citation needed]

In Russia, the products include yogurt, yogurt drinks, and kefir, a drink traditionally popular in Commonwealth of Independent States countries. The fiber yogurt series includes three muesli flavors in addition to the oat cereal flavor found in the US and UK. Drinkable yogurt variations include pineapple and dried apricot, among others. In 2023 Danone has decided to localize the international brand Activia under the new name AktiBio on the Russian market. The changes will concern only the brand name and packaging design.[citation needed]

United Kingdom and Ireland

[edit]

In Britain and Republic of Ireland, the Activia range includes:

Africa

[edit]

In the Republic of South Africa, flavors include pear, mango, dried apricot, kiwi, fiber and prune.

Australia

[edit]
  • 4-Pack: strawberry, natural, vanilla, fig, berries, mango[16]
  • Dessert: strawberry shortcake, apple strudel, passionfruit cheesecake
  • Favourites: vanilla berries mango, berries strawberry blueberry
  • Large Tub: strawberry, vanilla
  • Pouring: strawberry, mango, natural, vanilla
  • Singles: berries, strawberry, mango

Market

[edit]
Lactobacillus bulgaricus, also from a sample of Activia yogurt.[attribution needed]  The numbered ticks are 11 micrometres apart.

With its launch in France in the 1980s, Activia pioneered the probiotic spoonable yogurt market.[17]

In 2006, Activia sales reached $130 million, in the US alone. The following year, sales increased by 50% in the US market.[18]

In 2009, sales of Activia reach €2.6 billion globally, with key markets in Europe and the United States.[17] Activia's popularity in the United States is due to the growing public demand for natural products as well as the growing market of probiotics that came into vogue in the late 1990s.[19]

In 2010, Activia dominated the probiotic dairy sector.[20] The success of Activia has increased the health yogurt market.[21]

Activia, Actimel and Danonino account for more than half of the total worldwide yogurt sales.[22] Activia is a more than 2 billion-dollar brand which owes its success to the health benefit claim.[21]

In 2011, Activia was the largest global fresh dairy brand in the world (Nielsen data). The probiotic yogurt market is valued at €4 billion.[23]

Activia is present in more than 70 countries and is one of the major brands of the Danone Group.[9]

The probiotics market

[edit]

Activia products are considered as functional foods. These foods are enriched with probiotics and provide health benefits when consumed in adequate amounts. The positive effects depend on the specific strain and its dose.[24]

In 2003, the probiotics (also called functional foods) market was worth $9.9 billion.[25] These products are also heavily marketed and more expensive than non-probiotic dairy products.

In 2009, in the United Kingdom, 60% of households regularly bought probiotic drinks. The market there is currently worth £164m per year.[5]

Consumers are willing to pay for products that provide health benefits.[26] Activia products, that are considered as functional foods, are priced about two dollars higher than other yogurts.

Communication

[edit]

Since Activia's launch, the Danone Group focused Activia communication on probiotics and health benefits. In 2010, Dannon partnered with actress Jamie Lee Curtis to promote Activia products.[27] These advertisements described Activia as "scientifically proven" to reduce irregularity. According to the brand, Activia "helps regulate your digestive system" when eaten on a daily basis.[28] However, Danone has been accused of deceptive advertising.[29]

After the US litigation and the EU health claims law, and just before the decision of the EFSA on Activia, Danone decided to change communication and marketing for Activia. Advertising no longer mentions health benefits, focusing instead on pleasure and taste.[30] Danone's website contains the text: "Drinking and eating are, first and foremost, a source of pleasure, and while the initial purchase of a product may be motivated by a health benefit, in the majority of cases, a repeat purchase is motivated by the taste".[31]

Debates surrounding health claims on probiotic foods

[edit]
See also: Health claims on food labels

While indicating Bifidobacterium lactis, the package does not list that Activia also contains strains[32] commonly found in Yogurt: Lactobacillus bulgaricus, Streptococcus thermophilus (that produce high amounts of biogenic amines,[33][34] poorly tolerated by people with histamine intolerance) and Lactococcus lactis.

Some experts say there is evidence that probiotic strains reduce diarrhea, irritable bowel syndrome and duration of colds.[35][36] But others argue that their benefits are not certain.[25]

The US FDA pressed charges for false advertising.[37]

According to Danone, Activia is based on 17 scientific studies.[23][38] But according to CBS News, two of these studies were not statistically significant compared to the placebo groups[39] and six others did not show a statistically significant improvement in transit time.[40]

The EU health claims law

[edit]

Since 2007, European Regulation 1924/2006 demands that health food companies come up with the scientific evidence to back their labeling and advertising.[41][42] Member states are asked to submit health claims from manufacturers who have to wait for the approval of the European Food Safety Authority (EFSA). EFSA verifies all functional foods claims.[5] Most of the time, EFSA rejects companies' claims due to the lack of scientific evidence.[43]

In 2010, following a stream of negative opinions from EFSA for other health claims, Dannon decided to withdraw claims on Activia.[5]

Controversies in the United States

[edit]

Litigation in 2010

[edit]
Streptococcus thermophilus, also from the same sample of Activia yogurt.[attribution needed]  Numbered ticks are 11 micrometres apart.

In its marketing for Activia, Danone claimed that Bifidobacterium animalis relieves irregularity.

In the 2010 Activia TV commercials, a voiceover explains: "Activia eaten every day is clinically proven to help regulate your digestive system in two weeks". Danone said it had scientific evidence to back up its assertions.[44]

But according to the Federal Trade Commission, commercials and claims on Activia packages are deceptive and Danone exaggerates the yogurt's health benefits.[45] In its 2010 charges against Danone, the FTC stated that "Eating one serving of Activia daily is not clinically proven to relieve temporary irregularity and help with slow intestinal transit time".[39] In fact, consumers must eat three servings of Activia each day to obtain health benefits.[44]

In December 2010, The Danone Company settled allegations of false advertising. In the settlement, Danone dropped its claims of the health benefits of its Activia yogurt.[46] The company thus agreed to stop advertising that Activia yogurt improves motility, unless the ad conveys that three servings must be eaten per day to obtain these benefits. Danone therefore removed the words "clinically" and "scientifically proven" from Activia products.[47]

Danone agreed to pay US$21 million to 39 states that had coordinated investigations with the FTC.[48][49] In response to a similar lawsuit in Canada, Danone agreed to settle the suit by paying compensation and modifying its advertising.[6]

Class action in 2008–2009

[edit]

A class action lawsuit filed in Los Angeles federal court on 25 January 2008, argued that Danone's own studies failed to support its advertised claims.[50] The class action suit accused Danone of mounting a massive false advertising campaign to convince consumers to buy Activia products because of their health benefits.[51]

In a statement in response to the lawsuit, Danone stated that it "strongly disagrees with the allegations in the lawsuit" and that it makes all scientific studies about its products available to the public, following the established method of peer-review and publication.[52] According to the group: "All of Dannon's claims for Activia and DanActive are completely supported by peer-reviewed science and are in accordance with all laws and regulations".[53]

In 2009, as a part of the settlement, Danone agreed to create a $35 million fund to reimburse unsatisfied consumers who had bought its Activia and DanActive yogurts.[54]

Danone spokespeople deny the claims of the lawsuit and admitted no wrongdoing as part of the settlement, and they state that they only agreed to the settlement in order to "avoid the distraction and expense of litigation".[55] As of September 2012, this fund had only paid out about US$1 million in reimbursements to consumers.[6]

Litigation in Canada in 2009

[edit]

In October 2009, Danone was sued in Quebec Superior Court over the nature of the health claims in its advertising.[6] The company had asserted that Activia yogurt could improve digestion or prevent the common cold.[6] In September 2012, the parties elected to settle the case; Danone agreed to modify its advertising claims, but was not forced to admit wrongdoing.[6] Consumers who purchased Activia yogurt between 1 April 2009 and 6 Nov 2012 had 90 days to request compensation between C$15 to C$50, based on the quantity purchased.[6]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Activia

View on Grokipedia
from Grokipedia
Activia is a brand of produced by the Group, a French multinational food company, featuring the bacterial strain Bifidobacterium animalis subsp. lactis DN-173 010 (marketed as Bifidus Regularis in ). Introduced in in the late 1980s following research into bifidobacteria's role in gut health, it entered the U.S. market in 2006 as a product claiming to support digestive regularity and reduce minor issues like through daily consumption of live cultures. The yogurt's defining characteristic is its emphasis on , with each serving containing billions of the proprietary strain intended to transit the gut alive and influence composition. Company-sponsored clinical trials, involving healthy adults, reported small reductions in intestinal transit time and symptom relief after two weeks of twice-daily intake, forming the basis for that positioned Activia as superior for gut wellness. However, these findings relied on limited sample sizes and did not demonstrate benefits extending beyond those of standard yogurts with live cultures, prompting regulatory intervention. Activia's commercial success, driving substantial revenue for 's essential dairy division, has been marred by controversies over , culminating in a 2010 U.S. settlement requiring to abandon implications of unique efficacy and pay $21 million in penalties for deceptive practices. Concurrent class-action lawsuits alleging led to a $45 million consumer reimbursement fund, highlighting discrepancies between promoted outcomes and empirical evidence from broader research, which indicates potential general benefits but insufficient strain-specific proof for regularity claims. Recent independent trials have further cast doubt on its effectiveness for , underscoring that while may aid some digestive functions, Activia's has often exceeded verifiable causal effects.

History

Origins and Development

Activia originated from research conducted by scientists in the 1980s, focusing on incorporating bifidobacteria into to enhance digestive health properties. Traditional production involved at approximately 43°C, which proved inhospitable to bifidobacteria survival. In 1985, developed a combination of bacterial strains including Bifidobacterium lactis CNCM I-2494 (also known as Bifidus Regularis or DN-173 010), but initial attempts failed due to the high temperatures killing the . To overcome this, researchers innovated a specialized fermentation process using a blend of yogurt ferments— and Lactobacillus bulgaricus—adapted to lower temperatures around 37°C, mimicking conditions. This allowed for an extended 8-hour slow , enabling the bifidobacteria to proliferate to billions of live cultures per serving while producing a milder, creamier texture. The process balanced acidity and viability, ensuring the could withstand gastric transit. Activia was first launched in in 1987 as a probiotic-enriched stirred , marking Danone's targeted entry into functional dairy products emphasizing support. This development built on the company's century-long expertise, initiated by founder in 1919, but represented a distinct advancement in strain selection and for probiotic efficacy. Early formulation prioritized the exclusive strain's stability, setting Activia apart from standard yogurts.

Initial Launch and Early Growth

Danone launched Activia in France in 1987 as a probiotic yogurt designed to promote digestive regularity through daily consumption, featuring the Bifidobacterium strain in a specialized low-temperature fermentation process to enhance bacterial viability. The product differentiated itself from standard yogurts by emphasizing functional health benefits, drawing on research into gut microbiota and fermented dairy's role in transit time regulation. Initial market reception in capitalized on growing European interest in health-oriented dairy products during the late , with Activia—initially marketed under variants like Bio—pioneering the integration of bifidobacteria into spoonable s for broader probiotic accessibility. This positioned it as an early leader in the emerging functional foods category, supported by Danone's established yogurt expertise stemming from its 1919 origins in fermented products. Early expansion across followed the French debut, with the brand achieving steady adoption amid rising demand for digestive health solutions; by the early , it had solidified as a key offering, evidenced by global compounded annual sales growth of 24 percent from 2000 to 2004. This trajectory reflected consumer responsiveness to substantiated claims of improved intestinal comfort, though independent verification of long-term efficacy remained limited to company-backed studies during this period. By 2005, Activia ranked among Danone's top global sellers, paving the way for further international rollouts.

Global Expansion

Activia was initially launched in in 1987 as a featuring a proprietary blend of ferments designed to support the survival of at lower temperatures, marking Danone's entry into the functional segment. The product rapidly gained traction in , with early expansions into markets like by the late 1980s, leveraging Danone's established dairy infrastructure to distribute the probiotic-enriched across the continent. Entry into North America followed in the mid-2000s, beginning with a launch in , , in 2004, where it quickly captured significant market share and became the leading brand within three years. This success prompted further investment, including tailored marketing emphasizing digestive benefits. In 2006, Danone introduced Activia in the United States, positioning it as a gut aid amid rising consumer interest in , which drove substantial initial sales volumes and contributed to category expansion. Subsequent global rollout extended to , , and the , supported by localized production facilities and adaptations to regional tastes, such as fruit variants suited to emerging markets. By the , Activia had become a cornerstone of Danone's international portfolio, underpinning like-for-like sales growth in essential products, which rose 4.3% in 2024 driven partly by volume increases in yogurts. Recent developments, including new product lines like extensions in 2024, reflect ongoing efforts to deepen penetration in high-growth regions like and . In the U.S., surging demand has necessitated facility expansions to meet production needs.

Product Details

Core Ingredients and Formulation

Activia yogurt is formulated from cultured Grade A reduced-fat or non-fat milk as the primary base, which undergoes pasteurization followed by fermentation with live bacterial cultures. The core microbial components include the standard yogurt starter cultures Lactobacillus bulgaricus and Streptococcus thermophilus, supplemented by Lactococcus lactis and the proprietary probiotic strain Bifidobacterium animalis subsp. lactis DN-173 010 (also designated CNCM I-2494). This strain-specific combination, totaling five bacterial strains in some formulations, distinguishes Activia from conventional yogurts by aiming to deliver viable probiotics through the digestive tract. The fermentation process differs from typical yogurt production by employing a slower incubation at approximately 37°C, which supports the growth and viability of the anaerobic strain alongside the facultative anaerobes. Post-fermentation, the yogurt is cooled and may incorporate stabilizers such as modified food starch, , milk protein concentrate, or kosher to achieve desired texture, along with sweeteners like cane in non-zero-sugar variants or from chicory root in prebiotic-enhanced or no-added-sugar options. Flavored variants add preparations, natural flavors, or colorants like vegetable juice, while ensuring at least 10^8 to 10^9 colony-forming units (CFU) of the Bifidobacterium strain per serving for efficacy.
Key Bacterial Strains in ActiviaRole
Lactobacillus bulgaricusYogurt starter; contributes to acidification and texture.
Streptococcus thermophilusYogurt starter; aids fermentation and flavor development.
Lactococcus lactisSupports fermentation consistency.
Bifidobacterium animalis subsp. lactis DN-173 010Proprietary probiotic; targeted for gut transit survival.
This formulation prioritizes maintaining live cultures through refrigerated storage and minimal processing post-fermentation to preserve counts, though exact CFU levels can vary by product variant and regional specifications.

Probiotic Strain:

Bifidobacterium animalis subsp. lactis DN-173 010, also designated CNCM I-2494, is the proprietary probiotic strain central to Activia's formulation, developed and patented by for use in its fermented dairy products. This gram-positive, rod-shaped, anaerobic bacterium belongs to the genus , which is indigenous to the human and known for fermentation yielding lactic and acetic acids as primary metabolites. Unlike conventional cultures, this strain is specifically selected for its resilience to acidic environments and salts, enabling survival during gastric passage. In Activia yogurt, the strain is incorporated at initial concentrations exceeding 10^7 colony-forming units (CFU) per gram, co-cultured with Lactobacillus bulgaricus and to achieve the product's fermented texture and flavor, while maintaining probiotic viability through refrigerated storage. Enumeration methods confirm that viable cells of DN-173 010 persist at detectable levels (typically >10^6 CFU/g) by the product's expiration, supporting delivery of live to the consumer. Selective culturing techniques, such as those using reinforced clostridial supplemented with antibiotics, distinguish this strain from background in commercial samples. Molecular assays, including PCR targeting strain-specific genetic markers, have verified the recovery of live DN-173 010 from human fecal samples following consumption, demonstrating gastrointestinal transit survival rates sufficient for colonic colonization potential. Strain-specific traits, such as enhanced adhesion and short-chain production, differentiate it from other Bifidobacterium variants, underpinning Danone's emphasis on proprietary efficacy over generic effects. Independent viability assessments in similar fermented milks report logarithmic reductions of less than 1 CFU over 28-day under 4°C conditions, attributable to the strain's acid and oxygen tolerance.

Product Variants and Innovations

Activia is produced in spoonable formats, typically in single-serve cups or multipacks, featuring the core probiotic strain alongside standard yogurt cultures. Common flavors include , , , mixed berry, black cherry, and plain varieties, with nutritional profiles varying by type: low-fat options contain approximately 90 calories, 1.5g fat, 12g sugars, and 4g protein per 4oz serving. Some formulations offer 0g through sweetened variants using alternative ingredients. Drinkable variants, such as Activia Pourable and probiotic drinks, provide a liquid alternative for on-the-go consumption, retaining the probiotic content while available in flavors like strawberry-banana, peach, and raspberry. These typically deliver 70 calories and 9g sugar per serving, with Activia+ drinkable yogurts incorporating added vitamins C, D, and for 20% of the daily value to support immune function alongside gut health claims. In select markets, Activia includes drinkable Rayeb, a fermented product akin to drinks. Innovations have focused on enhancing nutritional profiles and consumer appeal, including a 2019 launch of live culture smoothies emphasizing no added sugar and fruit content. More recently, in July 2025, introduced Activia Proactive, a low-fat, thick-textured line fortified with 3g of prebiotic fiber per serving to complement the , available in multipacks of , , mixed , and flavors, and positioned as a source of calcium and . This update coincided with a refresh incorporating five strains for broader digestive support. European markets saw packaging redesigns to emphasize functionality and taste.

Scientific Basis for Health Claims

Claimed Digestive Benefits

Activia yogurt, produced by Danone, is promoted for its potential to support digestive health primarily through the inclusion of the probiotic strain Bifidobacterium animalis subsp. lactis DN-173 010, marketed under the trademark Bifidus Regularis, alongside standard yogurt cultures. The company claims this formulation contributes to a balanced gut microbiota, which in turn aids overall gastrointestinal function. Danone specifically asserts that consuming Activia twice a day for two weeks, as part of a balanced diet and healthy , may help reduce the frequency of minor digestive discomfort, including symptoms such as , gas, abdominal discomfort, and rumbling. These claims are positioned as arising from the probiotic's ability to reach the intestines alive in sufficient quantities to exert beneficial effects. In some markets, Activia products are described as containing billions of from a mix of strains that support digestive , with additional nutrients like calcium contributing to daily intake. The branding emphasizes these benefits without unsubstantiated promises of treating clinical conditions, reflecting post-2010 regulatory adjustments that curtailed earlier assertions about relieving temporary irregularity or accelerating intestinal transit.

Company-Funded Studies and Evidence

Danone has sponsored over 18 clinical studies on the probiotic strain Bifidobacterium animalis subsp. lactis DN-173 010 (CNCM I-2494), the key active ingredient in Activia yogurt, focusing on its survival in the gastrointestinal tract, impact on gut microbiota, and effects on digestive transit and symptoms. Early research emphasized objective measures like colonic transit time. In a double-blind, controlled trial published in 2001, 72 healthy adults consumed three 125g servings daily of fermented milk containing the strain for 11 days, resulting in a significant reduction in total colonic transit time compared to a control product without the probiotic (p<0.05). Similarly, Marteau et al. (2002) conducted a randomized, double-blind, crossover study with 32 healthy women ingesting three 125g servings per day for 10 days, which shortened total and sigmoid colonic transit times (p<0.05). Subsequent company-funded trials shifted toward subjective outcomes in populations reporting minor digestive issues. Guyonnet et al. (2009) reported in a randomized, double-blind, parallel controlled study involving 197 women consuming two 125g servings daily for four weeks a significant improvement in gastrointestinal well-being (odds ratio 1.69, p=0.006) and reduction in digestive symptom scores (least squares mean difference -0.57, p=0.044). A follow-up pooled analysis of this trial and Marteau et al. (2013)—another double-blind study with 324 women showing a symptom score reduction (p=0.033)—confirmed benefits in a meta-analysis of 538 participants, with decreased composite digestive symptom scores by week 2 (p<0.001). These effects were attributed to the strain's survival and colonization potential, as evidenced by studies like Pochart et al. (1992), where viable cells were detected in ileal effluent after a single dose (peak 6.3 × 10^8 CFU/hour). In irritable bowel syndrome with constipation (IBS-C) subgroups, Agrawal et al. (2009) found in a randomized, double-blind trial of 38 women that two daily 125g servings for four weeks reduced maximal abdominal distension by 77.1% (p<0.05) and colonic transit time by 12.2 hours (p=0.026). Mechanism-focused research, such as Tillisch et al. (2013), a double-blind trial with 38 women, linked consumption to decreased brain reactivity in regions processing visceral signals (p<0.0001), suggesting gut-brain axis modulation. Danone-funded survival studies consistently demonstrate the strain's viability through gastric and intestinal barriers, with fecal detection at 10^8 CFU/g in multiple participants after dosing. However, these trials typically involved healthy or mildly symptomatic adults, with dosages of two to three servings daily yielding modest improvements in transit (e.g., 10-12 hours reduction) and self-reported symptoms, without assessing severe irregularity or bloating in unaffected baselines.
StudyYearDesignParticipantsKey Outcome
Bouvier et al.2001Double-blind, controlled72 healthy adultsReduced total colonic transit time (p<0.05) with 3×125g/day for 11 days.
Marteau et al.2002Randomized, double-blind, crossover32 healthy womenShortened colonic transit times (p<0.05) with 3×125g/day for 10 days.
Guyonnet et al.2009Randomized, double-blind, parallel197 women with minor symptomsImproved GI well-being (OR=1.69, p=0.006); reduced symptoms (p=0.044) with 2×125g/day for 4 weeks.
Agrawal et al.2009Randomized, double-blind38 women with IBS-CReduced distension (p<0.05); colonic transit -12.2h (p=0.026) with 2×125g/day for 4 weeks.
Pooled (Marteau/Guyonnet)2019Meta-analysis538 womenDecreased symptom scores (p<0.001) by week 2.

Independent Research and Limitations

Independent randomized controlled trials have demonstrated that consumption of Bifidobacterium animalis subsp. lactis DN-173 010, the probiotic strain in Activia, can shorten colonic transit time by approximately 10-15 hours in healthy women compared to placebo, as measured by radiopaque markers or scintigraphy in double-blind studies involving 20-60 participants over 10-21 days. Similar effects on transit time and reduced bloating have been observed in subsets of patients with irritable bowel syndrome with constipation (IBS-C), where daily intake for 4 weeks improved stool frequency by 1-2 bowel movements per week and health-related quality of life scores, though not all symptoms resolved. In pediatric populations with functional constipation, the strain increased stool frequency modestly (from 2.2 to 3.3 per week) but failed to achieve clinically meaningful relief in a majority of cases, per a 2011 multicenter trial with 180 children. Broader meta-analyses of probiotics, including trials with DN-173 010, indicate a statistically significant reduction in whole gut transit time by 12-15 hours across 11-31 studies (n=1,000-2,000 participants), with greater effects in constipated individuals than healthy ones, but high heterogeneity (I² >50%) due to strain variations, doses (10^8-10^9 CFU/day), and populations limits generalizability. These analyses highlight strain-specificity, where DN-173 010 shows consistent but modest benefits for transit compared to other strains, yet efficacy diminishes in non-constipated adults and requires daily consumption without proven long-term persistence. Key limitations of independent research include small sample sizes (often <100 per arm), short intervention periods (≤4 weeks), and reliance on self-reported outcomes like alongside objective measures, which introduce subjectivity and potential despite blinding. Few purely independent, large-scale trials exist specifically for DN-173 010 outside industry collaborations, with most evidence derived from a handful of European RCTs prone to favoring positive results; negative or null findings, such as no defecation promotion despite transit shortening, are underrepresented. Benefits are not universal, varying by baseline , diet, and genetics, and may partly stem from the fermented milk matrix rather than the alone, as plain yields comparable effects in some comparisons. Overall, while empirical data support minor improvements in transit for select groups, causal mechanisms remain incompletely elucidated, with calls for longer-term, diverse-population studies to confirm clinical beyond surrogate markers.

Marketing and Promotion

Advertising Campaigns

Activia's advertising campaigns have historically emphasized the probiotic strain Bifidobacterium animalis DN-173 010 (branded as Bifidus) for digestive regularity, often featuring testimonials and animations of gut activity. From 2006 to 2013, actress served as the primary spokesperson in U.S. television commercials, promoting the product as aiding "slow intestinal transit time" with taglines like "Activia helps with regularity." Curtis appeared in dozens of spots, portraying relatable scenarios of improved , which contributed to the brand's sales growth but also drew for overt focus on bowel movements. These early campaigns faced scrutiny for unsubstantiated claims, leading to a 2010 settlement with the U.S. (FTC) and multiple state attorneys general, where agreed to pay $21 million in penalties and cease assertions that one daily serving significantly improves digestion beyond general consumption or prevents illness. The FTC complaint highlighted nationwide ads exaggerating Bifidus's superiority over other yogurts' bacteria, prompting revised messaging to avoid implying unique clinical benefits without stronger evidence. Post-settlement, campaigns pivoted toward broader "gut health" narratives linking digestion to overall , as seen in the 2020 "A to Z" initiative featuring diverse spokespeople discussing gut-brain connections and launching a "Gut Health Challenge" for consumer engagement via . This included multicultural marketing expansions, with increasing diverse ad spend since 2021 to target underrepresented groups. By 2022, Activia shed its niche digestive-aid image through trendy wellness ads aligning with consumer shifts toward holistic , incorporating viral elements like a 2014 Shakira-fronted spot that became one of the most-shared commercials ever. Recent efforts, such as the 2025 "Gut Glow-Up" campaign, leverage influencers and digital platforms to appeal to Gen Z and , emphasizing proactive gut care without Curtis-era specificity.

Rebranding Efforts

In 2016, undertook a global re-launch of Activia, introducing a new visual identity and packaging design to position the brand as more premium and aligned with modern consumer expectations for digestive products. This effort followed observations of declining popularity attributed to an outdated marketing strategy disconnected from contemporary wellness trends. By 2017, in the United States, Activia launched the "It Starts Inside" campaign as part of a national initiative, emphasizing internal and gut benefits targeted at women, with updated messaging to foster emotional connections beyond functional claims. In March 2024, announced a in the , featuring a revised focused on digestive , provision, and support, alongside refreshed to maintain relevance amid evolving consumer preferences for gut products. Most recently, in July 2025, Activia executed a significant brand refresh in , including the launch of the Activia Proactive line with approximately 25% less sugar, simpler ingredients, and modernized packaging under the "Gut Glow-Up" campaign. This update aimed to appeal to younger demographics like Gen Z and through influencer partnerships and a science-backed repositioning, while preserving core credentials for existing consumers.

Consumer Perception and Sales Impact

Activia's marketing campaigns, featuring endorsements from celebrities like , have cultivated a among consumers of the product as an effective for digestive regularity, contributing to its positioning as a premium . A 2021 analysis noted that Activia successfully built a loyal base of wellness-focused shoppers prioritizing gut , aligning with broader consumer interest in , where surveys show they are perceived as supporting digestive and overall . However, consumer surveys reveal mixed sentiments, with 33% of respondents in a 2024 study expressing overwhelm from the volume of gut health claims across products, potentially diluting trust in specific brands like Activia. Taste remains a primary driver of yogurt purchases, with 48% of consumers citing it as a top factor in a 2021 international survey, influencing Activia's appeal despite its higher price point compared to plain yogurts. Choice experiments on probiotic yogurts indicate strong valuation of health labels and probiotic strain diversity, bolstering Activia's premium perception, though independent verification of efficacy varies. The brand's aggressive advertising has directly correlated with sales surges; following its U.S. launch, Activia generated over $130 million in its first year, establishing it as a blockbuster in the category. Rebranding efforts from 2020 onward, including the "A-to-Z" campaign linking gut health to emotional well-being, supported 31 consecutive weeks of growth through early 2021, with February sales up 3.6% year-over-year. By 2024, Activia contributed significantly to Danone's segment, which saw 5% U.S. sales growth in the third quarter per IRI data, amid overall company volume/mix expansion of 3%. Post-2010 regulatory settlements over exaggerated claims temporarily stabilized U.S. at 7.1-7.2%, but subsequent wellness-focused innovations and expansions, including a 2025 U.S. facility upgrade amid "explosive growth," have driven recovery and sustained Activia as Danone's top global brand, accounting for over 60% of essential products revenue in key markets. In the broader U.S. market, valued at $11.8 billion for the 52 weeks ending 2025 with 11.6% year-over-year growth, Activia benefits from the subcategory's momentum while facing competition from high-protein alternatives.

Controversies and Criticisms

Exaggerated Health Claims

Danone marketed Activia yogurt as containing the proprietary probiotic strain Bifidobacterium lactis DN-173 010 (branded as Bifidus Regularis), claiming it could relieve temporary digestive discomfort, such as and irregularity, and help regulate slow intestinal transit time more effectively than ordinary yogurt. These assertions were supported primarily by company-funded studies showing modest reductions in transit time—typically 10-20% after consuming two servings daily for two weeks in healthy women with self-reported slow transit—but regulators determined the evidence did not substantiate benefits for the general population or at the one-serving-per-day level promoted in . The (FTC) charged with deceptive practices in 2010, noting that the claims implied superior efficacy unsupported by robust, independent data, as the trials involved small samples (often under 100 participants), lacked broad applicability, and failed to demonstrate clinically meaningful differences beyond general effects from live cultures in standard . This led to a settlement requiring to discontinue unsubstantiated claims, pay $21 million to 39 states, and refrain from representing Activia as treating irregularity unless backed by at least two adequate, well-controlled studies. Separate class-action lawsuits, culminating in a settlement of up to $45 million for U.S. consumers, alleged that the justified a 30% price premium by overstating strain-specific benefits, which independent reviews have since critiqued as negligible or placebo-equivalent in larger randomized trials for gut health outcomes. Recent meta-analyses and controlled studies reinforce skepticism, finding inconsistent evidence for B. lactis strains improving bowel regularity beyond or conventional , with effects often vanishing in rigorous, non-industry-funded research.

Skepticism from Scientific Community

Scientific experts have questioned the extent to which Activia's proprietary Bifidobacterium lactis DN-173 010 strain, branded as Bifidus Regularis, delivers superior digestive benefits compared to standard cultures like Lactobacillus bulgaricus and . A 2008 in the , involving 75 healthy women, found that consuming Activia twice daily for two weeks shortened colonic transit time by approximately 1.13 hours relative to a control but failed to increase stool frequency or consistency, leading researchers to conclude there is insufficient evidence to substantiate claims of promoted . Medical researchers, including gastroenterologists interviewed in 2008, have emphasized the need for larger, independent clinical trials to confirm efficacy, stating that while Activia and similar products pose no safety risks, their impact on gut health in healthy populations remains under-evidenced and potentially overstated by . Broader reviews of , including those specific to strains, indicate minimal colonization of the human gut by ingested bacteria due to barriers and competition from resident , with meta-analyses showing no consistent benefits for transit time or symptom relief in individuals. In 2010, the U.S. cited inadequate substantiation from well-designed, peer-reviewed studies for Dannon's assertion that one daily serving of Activia relieves temporary irregularity, requiring the company to limit future claims to effects observed only after multiple servings over extended periods. Danone's 2011 withdrawal of health claim dossiers for Activia submitted to the further underscored evidentiary gaps, as the firm attributed the decision to unclear regulatory criteria but acknowledged challenges in demonstrating causality for digestive symptom reduction under stringent scientific standards. This pattern aligns with critiques that many studies, including early Activia trials, rely on industry sponsorship, which can introduce toward positive outcomes without robust replication by disinterested parties.

United States Litigation and Settlements

In 2007, multiple class action lawsuits were filed against The Dannon Company in U.S. federal courts, alleging false and misleading claims that Activia yogurt's strain Bifidobacterium animalis DN-173 010 (marketed as Bifidus Regularis) provided superior digestive health benefits, such as improved regularity and transit time, beyond those of ordinary , when consumed in one daily serving. Plaintiffs contended these claims relied on company-sponsored studies with methodological limitations, including small sample sizes and reliance on self-reported symptoms rather than objective measures, failing to demonstrate clinically meaningful effects at the advertised dosage. On September 18, 2009, Dannon reached a preliminary settlement in the multidistrict litigation consolidated in the U.S. District Court for the Northern District of Ohio, creating a $35 million common fund to compensate consumers who purchased Activia or DanActive products from January 1, 2006, to the settlement date, without admitting wrongdoing or liability. Eligible claimants received up to $15 via online submission without proof of purchase, $30 with a paper form, or $100 with receipts demonstrating multiple purchases. The settlement also required changes to product labeling and advertising to avoid unsubstantiated superiority claims. On February 23, 2010, U.S. District Judge Dan Aaron Polster approved the agreement, authorizing payouts up to $45 million based on claim volume, with $10 million allocated to plaintiffs' attorneys' fees. Concurrently, the (FTC), in coordination with 39 state attorneys general, investigated Dannon for deceptive practices under Section 5 of the FTC Act, focusing on unsubstantiated representations that Activia "helps regulate the digestive system with just one 4-oz. serving a day" and similar immune or digestive claims for DanActive. On December 15, 2010, Dannon settled without admitting fault, agreeing to pay $21 million to the states for consumer redress and investigation costs, and to refrain from claims unless backed by at least two randomized, double-blind, placebo-controlled clinical trials showing . The FTC stipulated that Dannon's prior evidence, primarily from short-term studies on higher consumption levels (e.g., two to three servings daily), did not support the one-serving efficacy advertised to the general population. No major additional U.S. litigation against Activia's claims has resulted in settlements post-2010, though the precedents influenced stricter substantiation standards for advertising.

International Regulations and Cases

In the , withdrew advertising claims for Activia and asserting specific health benefits, such as aiding digestion or boosting immunity, following scrutiny from the (EFSA). This action in April 2010 came after resubmitted and then voluntarily pulled applications to EFSA, amid requirements for substantiated evidence under EU nutrition and health claims regulations (Regulation (EC) No 1924/2006). The withdrawals applied across EU member states, leading to modify promotional materials to avoid implying superior effects beyond general benefits. In Canada, Danone Canada settled a class-action lawsuit in September 2012 over misleading health claims on Activia packaging and advertisements, which stated the product could regulate digestion or boost the immune system with Bifidus Regularis probiotic. The settlement required a CAD $1.7 million payment to affected consumers who purchased the products between 2005 and 2012, without admitting liability, and mandated revised labeling to align with Health Canada guidelines emphasizing evidence-based probiotic efficacy. The case highlighted tensions between commercial strain-specific claims (e.g., Bifidobacterium lactis DN-173 010 surviving transit to regulate gut flora) and regulatory demands for robust clinical proof of benefits in the general population. Switzerland diverged from broader EU trends when, in March 2013, authorities approved a front-of-pack for Activia stating it "aids ," based on reviewed evidence of the 's role in improving transit time in select studies. This approval under Swiss food law permitted limited promotional use, contrasting with EFSA's stricter substantiation thresholds that rejected similar claims elsewhere in due to insufficient generalizability from trial data involving constipated or elderly participants. No major additional international lawsuits or regulatory bans have been reported post-2013, though ongoing monitoring by bodies like Australia's Food New Zealand enforces pre-approval for novel claims.

Post-2010 Developments

In 2011, the U.S. approved its final order settling charges against The Dannon Company for deceptive claims regarding Activia and DanActive drink, prohibiting assertions that one serving per day relieves temporary irregularity or helps with slow intestinal transit time unless supported by competent and reliable scientific evidence, while allowing more limited claims about regularity with two servings daily based on prior studies. This followed the December 2010 agreement, under which Dannon paid $21 million to 39 states for advertising investigations, without admitting wrongdoing. In September 2012, settled a class-action initiated in 2009, agreeing to pay approximately CAD 2 million (USD $1.7 million) to eligible consumers who purchased Activia, Activia Light, or DanActive products after , 2009, in response to contested claims about boosting immunity and aiding ; the settlement, finalized without admission of liability, also required adjustments to future and labeling to align with substantiated . In the , the implementation of Regulation (EC) No 1924/2006 on nutrition and health claims, effective from 2010, imposed stringent requirements for probiotic-related assertions, leading to withdraw or modify claims for Activia after the (EFSA) scrutinized submissions for insufficient evidence on benefits like gut health; by 2010-2012, EFSA rejected broad claims for live yogurt cultures beyond in lactose-intolerant individuals, prompting industry-wide caution and 's assessment that resubmissions were economically unviable due to rigorous substantiation demands. No major EFSA-approved health claims specific to Activia's Bifidus strains emerged post-2010, shifting marketing toward general nutritional attributes. A 2012 U.S. class-action suit in the Southern District of New York alleged Activia failed FDA yogurt standards of identity due to added fillers like modified , but the court dismissed it in 2013, ruling the product qualified as under federal definitions as it involved milk fermentation with bacterial cultures. Subsequent years saw no significant new litigation or regulatory enforcement against Activia's core positioning in major markets, reflecting stabilized claims post-settlements and adapted compliance with evidence-based standards.

Current Market Status

Global Presence and Sales Performance

Activia maintains a widespread international footprint, distributed in over 70 countries across five continents, including key regions such as the , , , and the Middle East-. The brand's expansion began in in the 1980s under , with subsequent launches in in 2006 and broader penetration into emerging markets in , , and through localized production and marketing adaptations. This global availability positions Activia as a dominant player in the probiotic yogurt category, leveraging 's manufacturing network of over 190 plants worldwide to ensure supply chain efficiency. In terms of sales performance, Activia serves as Danone's flagship brand within the Essential Dairy and Plant-Based (EDP) division, which generated approximately €13.5 billion in global sales in 2024, representing the company's largest revenue segment. More than 60% of EDP revenues derive from high-value functional products like Activia, emphasizing gut benefits that have sustained consumer demand amid shifting wellness trends. Danone reported like-for-like sales growth of 4.3% for the group in 2024, with EDP contributing through 3% volume/mix expansion following declines in prior years (-0.4% in 2023), attributed in part to Activia's refreshed formulations and focused on microbiome science. In , Activia has shown particular resilience, with ongoing innovations driving market share gains in the competitive sector valued at over USD 103 billion globally in 2024.

Competitive Landscape

Activia, a flagship brand under S.A., operates in a highly competitive market dominated by a few major players emphasizing differentiation through product attributes like protein content, flavor variety, and health claims. , where Activia holds a notable position in the probiotic subcategory, the overall market is led by with approximately 13% share as of 2025, followed by Danone's portfolio at 26%, at 11%, at 7%, and Siggi's at 6%. 's dominance stems from its focus on Greek-style , high protein formulations (often 15-20 grams per serving), and broad flavor innovation, appealing to fitness-oriented consumers, while Activia targets digestive health via its proprietary lactis strain. Yoplait, owned by General Mills, competes primarily in the flavored and spoonable segments with lower-price-point offerings and fruit-on-the-bottom varieties, capturing mass-market share but facing pressure from premium brands; its efforts, such as past Yo-Plus lines, have been discontinued, reducing direct rivalry in Activia's core gut-health niche. and Siggi's challenge Activia in the space, emphasizing thick texture and minimal ingredients— with authentic Greek heritage and Siggi's with Icelandic skyr-style low-sugar profiles—though neither matches Activia's strain-specific marketing. Private labels from retailers like and also erode margins by offering generic yogurts at 20-30% lower prices, comprising up to 15% of category sales. Globally, the probiotic yogurt submarket, valued at USD 31.38 billion in 2025 and projected to reach USD 67.75 billion by 2035, pits Danone against Nestlé, Yakult Danone India, Chobani, and Yili Group, with regional variations: Nestlé leverages Nesquik and Nido integrations for family-oriented probiotics in Europe and Asia, while Yili dominates China through localized dairy supply chains. Activia's competitive edge lies in its established Bifidus branding and clinical backing for transit-time benefits, though rivals counter with broader live-culture claims and plant-based alternatives amid rising non-dairy demand (e.g., Chobani's oat yogurts). Pricing strategies vary, with Activia's premium positioning (around USD 1.50-2.00 per 4-oz cup) facing erosion from Chobani's value packs and Yoplait's promotions, contributing to category dollar sales growth of 11.6% to USD 11.8 billion for the 52 weeks ending April 2025.

Recent Innovations and Challenges

In July 2025, launched Activia Proactive, a low-fat line featuring billions of live and active combined with 3 grams of prebiotic per serving to support gut , alongside reduced content (approximately 25% less than previous formulations) and simpler ingredient lists. The product, available in four flavors—Vanilla, , Mixed , and —in 4-count multipacks, also provides calcium and for bone , positioning it as an enhanced option for digestive regularity. This launch coincided with a brand-wide refresh aimed at modernizing Activia's to to younger consumers, including Gen Z and , through a "Gut Glow-Up" campaign emphasizing awareness. In , Danone introduced Activia EXPERT in August 2025, marketed as an advanced with an exclusive prebiotic-probiotic blend developed from 35 years of , targeting digestive and overall wellness benefits. These innovations reflect 's strategy to align with rising consumer demand for functional foods amid growing gut health interest, incorporating prebiotics to complement existing Bifidus strains. Challenges in these developments included reformulating products to cut sugar while preserving texture and flavor, a process described as technically demanding to avoid alienating core users. gaps persist, with a study indicating that about 50% of Americans remain unaware of the gut microbiome's role in health, complicating marketing efforts for probiotic-prebiotic synergies. Additionally, Activia faces intensified competition in the probiotic segment from plant-based alternatives and emerging functional brands, requiring influencer-driven tactics to engage demographics skeptical of traditional perceptions. These efforts aim to sustain without diluting evidence-based claims on transit time regulation, though independent verification of prebiotic enhancements' efficacy beyond company trials remains limited.

References

  1. https://temertymedicine.utoronto.ca/news/pioneering-study-shows-large-differences-probiotic-yogurt-health-benefits
  2. https://www.danone.com/brands/essential-dairy-and-plant-based-products/activia.html
  3. https://www.cnn.com/2022/07/03/business/activia-yogurt
  4. https://www.activia.us.com/our-story/
  5. https://www.cspi.org/sites/default/files/media/documents/resource/nah_probiotics.pdf
  6. https://www.activia.com.au/healthcare-professionals/probiotics-and-live-cultures/
  7. https://www.ftc.gov/news-events/news/press-releases/2010/12/dannon-agrees-drop-exaggerated-health-claims-activia-yogurt-danactive-dairy-drink
  8. https://abcnews.go.com/Business/dannon-settles-lawsuit/story?id=9950269
  9. https://www.health.harvard.edu/nutrition/the-benefits-of-probiotics
  10. https://www.insidehook.com/wellness/clinical-trial-probiotic-activia-gut-health
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4351195/
  12. https://www.ernaehrungs-umschau.de/fileadmin/Ernaehrungs-Umschau/Branchenverzeichnis/Danone/Facts_sheets_Activia_2020.pdf
  13. https://www.activia.com.au/the-birth-of-our-favorite-bifidus/
  14. https://www.nutraceuticalsworld.com/breaking-news/dannon-launches-new-yogurt-in-u-s/
  15. https://progressivegrocer.com/dannon-rolling-out-activia-probiotic-yogurt-us
  16. http://media.corporate-ir.net/media_files/irol/95/95168/annualreports/06_indexed/2DANRAP006_5NURITION_GB.pdf
  17. https://www.nutritionaloutlook.com/view/marketing-probiotics-past-present-market-has-been-friendly-friendly-bacteria
  18. https://www.danone.com/group/about-us/our-history.html
  19. https://www.sciencedirect.com/science/article/pii/S0022030217310524
  20. https://www.dairyfoods.com/articles/82889-yogurt-now-a-part-of-american-culture
  21. https://www.studocu.com/row/document/eslsca-business-school-paris-egypt/marketing-management/activia-in-egypt-case-study/63316598
  22. https://www.warc.com/content/article/cca/danone--activia-three-years-of-tasty-success/en-gb/87446
  23. https://www.danone.com/group/about-us/facts-and-figures.html
  24. https://dairynews.today/news/danone-s-activia-expands-portfolio-with-new-kefir-range-to-promote-gut-health.html
  25. https://www.just-food.com/news/danone-lines-up-yogurt-facility-expansion-amid-explosive-growth-in-us/?cf-view
  26. https://www.activia.us.com/probiotic-yogurt/probiotic-yogurt/4-pack/strawberry/
  27. https://www.danoneawayfromhome.com/food-service-products/activia-vanilla-4oz/
  28. https://www.activia.us.com/frequently-asked-questions/
  29. https://www.activia.ca/en/frequently-asked-questions/
  30. https://www.activia.com.au/our-famous-5-bacteria/
  31. https://www.danoneactivia.co.uk/article-how-do-probiotics-work/
  32. https://www.activia.us.com/probiotic-yogurt/zero-added-sugar/4-packs/zero-added-sugar-vanilla/
  33. https://www.activia.ca/en/products/activia-expert/activia-expert-yogurt/plain-probiotic-and-prebiotic-yogurt-no-added-sugar/
  34. https://shop.foodmaxx.com/store/foodmaxx/products/101191-activia-low-fat-probiotic-vanilla-yogurt-4-oz
  35. https://www.danoneactivia.co.uk/gut-science-hub/activia-science/strain-specificity/
  36. https://www.activia.us.com/frequently-asked-questions/activia-greek/
  37. https://www.webmd.com/vitamins/ai/ingredientmono-891/bifidobacterium-animalis-subsp-lactis
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC10942848/
  39. https://www.researchgate.net/publication/240762949_Rapid_method_for_selective_enumeration_of_Bifidus_essensis_in_ACTIVIA_yogurts
  40. https://pdfs.semanticscholar.org/3372/124a02fdcd731714bc3e0826efa2f84f015e.pdf
  41. https://www.sciencedirect.com/science/article/abs/pii/S0963996905002279
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4858658/
  43. https://www.researchgate.net/publication/314717654_Viability_of_Probiotic_Bacteria_during_Refrigerated_Storage_of_Commercial_Probiotic_Fermented_Dairy_Products_Marketed_In_Jordan
  44. https://www.danoneawayfromhome.com/food-service-products/activia-lowfat-yogurt-strawberry-black-cherry-and-peach-24-ct-variety-pack-4oz/
  45. https://www.activia.us.com/probiotic-products/
  46. https://www.danonenorthamerica.com/newsroom/details/new-activia-multi-benefit-drinkable-yogurt-with-added-nutrients-helps-support-your-immune-system.html.html.html.html
  47. https://www.danone.eg/our-brands.html
  48. https://www.foodbev.com/news/activia-debuts-new-proactive-yogurt-line-amid-brand-refresh
  49. https://www.prnewswire.com/news-releases/wellness-starts-from-within-activia-gut-glow-up-campaign-marks-new-modern-chapter-with-launch-of-activia-proactive-yogurt-and-product-refresh-302518711.html
  50. https://www.danone.com/brands/essential-dairy-and-plant-based-products.html
  51. https://portal.ct.gov/AG/Press-Releases-Archived/2010-Press-Releases/Attorney-General-Announces-Agreement-With-Dannon-Over-Activia-and-DanActive-Claims-About-Digestive-H
  52. https://guthealthchallenge.activia.us.com/
  53. https://activiaguthealthtoolkit.com/wp-content/uploads/2022/04/Activia_Probiotic_Pioneer_Download.pdf
  54. https://danone.strauss-group.com/wp-content/uploads/2020/05/Marteau-et-al-2002.pdf
  55. https://pubmed.ncbi.nlm.nih.gov/19622191/
  56. https://pubmed.ncbi.nlm.nih.gov/23480238/
  57. https://pubmed.ncbi.nlm.nih.gov/11876714/
  58. https://pubmed.ncbi.nlm.nih.gov/17635382/
  59. https://publications.aap.org/pediatrics/article/127/6/e1392/30089/Fermented-Milk-Containing-Bifidobacterium-lactis
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3732843/
  61. https://www.sciencedirect.com/science/article/pii/S0002916523047895
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC5949321/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC2799919/
  64. https://pubmed.ncbi.nlm.nih.gov/18461886/
  65. https://www.today.com/food/jamie-lee-curtis-reveals-why-she-did-activia-ads-years-t233485
  66. https://people.com/why-jamie-lee-curtis-did-yogurt-commercials-at-height-of-career-11733177
  67. https://www.atg.wa.gov/all-consuming-blog/activia-yogurt-ads-mostly-health-hype-say-attorneys-general
  68. https://www.activia.us.com/press/a-to-z-press-release/
  69. https://www.marketingdive.com/news/activia-uncaps-fresh-brand-image-with-diverse-campaign-on-gut-health/581116/
  70. https://digiday.com/marketing/activia-joins-brands-ramping-up-multicultural-marketing-efforts/
  71. https://www.mdgsolutions.com/learn-about-multi-location-marketing/activia-ad-starring-shakira-shakes-up-viral-video-history-to-become-most-shared-commercial-ever-2/
  72. https://www.foodnavigator-usa.com/Article/2025/09/29/activias-gut-glow-up-brand-refresh-and-proactive-launch/
  73. https://www.dairyreporter.com/Article/2025/09/29/danone-woos-gen-z-and-millennials-with-activias-modern-makeover/
  74. https://packagingoftheworld.com/2016/10/activia-global-brand-re-launch.html
  75. https://www.thedrum.com/news/2016/10/05/danones-global-activia-relaunch-aims-premiumise-the-yoghurt-brand
  76. https://shortyawards.com/7th/activia-dare-to-feel-good-campaign
  77. https://consumergoods.com/activia-empowers-women-inside-and-out
  78. https://www.trendhunter.com/trends/activia-rebranding
  79. https://health.yahoo.com/wellness/nutrition/healthy-eating/articles/activia-just-got-modern-makeover-160100349.html
  80. https://www.dairyfoods.com/articles/95050-activia-builds-a-base-of-wellness-focused-consumers
  81. https://nutraceuticalbusinessreview.com/probiotic-trends-consumer-preferences-shaping-the-landscape
  82. https://www.dairyreporter.com/Article/2024/05/29/gut-health-marketing-is-overwhelming-shoppers/
  83. https://www.fooddive.com/news/taste-is-tops-in-consumers-yogurt-priorities-survey-finds/601516/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC9460311/
  85. https://www.erudit.org/en/journals/cuizine/2014-v5-n1-cuizine01327/1024279ar/
  86. https://insights.citeline.com/RS150201/Activia-Going-With-Its-Gut-Targeting-Young-Consumers-In-Advertising-Probiotics-As-Cool/
  87. https://www.fooddive.com/news/Danone-Dannon-Activia-Oikos-yogurt-better-for-you/701158/
  88. https://www.danone.com/content/dam/corp/global/danonecom/investors/en-all-publications/2025/registrationdocuments/urd2024accessibleversion.pdf
  89. https://www.nytimes.com/2014/01/06/business/media/new-campaign-markets-activia-to-wider-audience.html
  90. https://www.innovamarketinsights.com/trends/yogurt-market-global-dairy-and-dairy-alternative-trends/
  91. https://www.dairyfoods.com/articles/98323-us-annual-yogurt-sales-close-in-on-12b-figure
  92. https://www.atg.wa.gov/news/news-releases/activia-yogurt-ads-mostly-health-hype-say-attorneys-general
  93. https://www.ftc.gov/news-events/news/press-releases/2011/02/ftc-approves-final-order-settling-charges-dannon-made-deceptive-claims-activia-yogurt-danactive
  94. https://badgut.org/information-centre/a-z-digestive-topics/dannon-lawsuit-settled/
  95. https://arstechnica.com/health/2024/10/popular-gut-probiotic-completely-craps-out-in-randomized-controlled-trial/
  96. https://medium.com/the-quantastic-journal/probiotics-dont-help-gut-health-18e73766ca3b
  97. https://www.cbc.ca/news/science/medical-experts-seek-proof-for-probiotic-health-claims-1.737354
  98. https://www.scientificamerican.com/article/do-probiotics-really-work/
  99. https://www.minnpost.com/second-opinion/2012/02/some-healthy-skepticism-about-probiotics/
  100. https://www.efsa.europa.eu/sites/default/files/event/documentset/110629-p08.pdf
  101. https://www.latimes.com/archives/la-xpm-2009-sep-19-fi-yogurt-settlement19-story.html
  102. https://centerforinquiry.org/wp-content/uploads/sites/33/quackwatch/casewatch/civil/dannon/settlement.pdf
  103. https://topclassactions.com/lawsuit-settlements/closed-settlements/dannon-activia-yogurt-class-action-lawsuit-settlement/
  104. https://www.cleveland.com/metro/2010/02/post_222.html
  105. https://www.ftc.gov/business-guidance/blog/2010/12/ftc-challenges-dannons-claims-activia-yogurt-danactive
  106. https://www.nytimes.com/2010/12/16/business/16yogurt.html
  107. https://www.nutraceuticalsworld.com/exclusives/probiotic-advertising-class-actions-claims-challenged-lessons-learned/
  108. https://www.france24.com/en/20100416-danone-advertising-claims-yoghurts-health-benefits-efsa
  109. http://news.bbc.co.uk/2/hi/8622017.stm
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC2739920/
  111. https://www.supplysidesj.com/claims/danone-pulls-yogurt-health-claims
  112. https://www.cbc.ca/news/canada/montreal/danone-agrees-to-pay-1-7m-in-yogurt-health-claims-case-1.1206623
  113. https://www.dairyreporter.com/Article/2012/09/25/Danone-settles-Canadian-Activia-health-claims-lawsuit/
  114. https://globalnews.ca/news/290618/danone-to-settle-lawsuit-over-activia-yogurt-danactive-health-claims/
  115. https://www.nutraingredients.com/Article/2013/03/22/Activia-health-claim-Danone-win-in-Switzerland/
  116. https://www.asa.org.uk/advice-online/food-probiotic-claims.html
  117. https://www.dairyreporter.com/Article/2012/09/25/Danone-settles-Canadian-Activia-health-claims-lawsuit
  118. https://www.nutraingredients.com/Article/2010/12/07/Danone-tells-EFSA-Health-claims-learning-experience-is-too-costly/
  119. https://www.efsa.europa.eu/en/efsajournal/pub/1763
  120. https://www.sdnyblog.com/judge-briccetti-rules-that-activia-yogurt-is-yogurt-dismisses-class-action/
  121. https://www.statista.com/topics/2428/danone/
  122. https://www.foodbusinessnews.net/articles/27789-danones-volumes-turn-positive-in-2024
  123. https://www.danone.com/newsroom/press-releases/2022-full-year-results-danone.html
  124. https://www.dairyreporter.com/Article/2025/02/04/danone-on-leveraging-biotics-to-advance-nutrition-and-gut-health/
  125. https://www.bonafideresearch.com/blog/top-companies-global-yogurt-market
  126. https://evidnt.co/insights/u-s-yogurt-market-trends-2025-top-brands-growth-drivers-and-emerging-consumer-shifts/
  127. https://www.mordorintelligence.com/industry-reports/united-states-yogurt-market/companies
  128. https://www.verifiedmarketresearch.com/blog/top-yogurt-brands/
  129. https://www.databridgemarketresearch.com/reports/us-yogurt-market
  130. https://www.futuremarketinsights.com/reports/probiotic-yogurt-market
  131. https://www.linkedin.com/pulse/industry-insider-global-probiotic-yogurt-market-dataintelosolutions-1wo4f
  132. https://www.dairyfoods.com/articles/98422-activia-champions-gut-health-with-new-proactive-line-unveils-brand-refresh
  133. https://nutraceuticalbusinessreview.com/introducing-activia-expert-canada-s-most-advanced-yoghurt-for
  134. https://dairynews.today/news/activia-s-gut-health-revival-navigating-science-and-consumer-trends.html
  135. https://perishablenews.com/dairy/activia-gut-glow-up-campaign-marks-new-modern-chapter-with-launch-of-activia-proactive-yogurt-and-product-refresh/
  136. https://www.dairyreporter.com/Article/2025/10/02/whats-the-next-frontier-of-functional-dairy-danone-tells-all/
Add your contribution
Related Hubs
User Avatar
No comments yet.